1/21/2021 7:11:50 AM
Sutro Biopharma : First Patient Dosed In Dose-Expansion Study Of STRO-002 In Patients With Ovarian Cancer
12/8/2020 9:44:55 PM
Sutro Biopharma Prices Public Offering Of 6 Mln Shares At $21.00/shr
12/7/2020 4:01:46 PM
Sutro Biopharma Announces Proposed Public Offering Of 5 Mln Shares Of Common Stock
12/7/2020 10:09:57 AM
Sutro Biopharma Presents Data From Ongoing Phase 1 Dose-Escalation Study For STRO-001
8/25/2020 7:19:25 AM
Sutro Biopharma Achieves Clinical Supply Milestone From Merck KGaA
6/9/2020 7:09:41 AM
Sutro Biopharma To Present New Preclinical Data On STRO-002 Antibody-Drug Conjugate At AACR On June 22
5/21/2020 7:20:02 AM
Sutro Biopharma Names Craig Berman VP Of Clinical Development; Promotes Regina Cheng To VP Of Finance And Controller
5/21/2020 7:12:18 AM
Sutro Biopharma Names Carlos Paya Chair Of Scientific Advisory Board And Lainie Martin Member Of Clinical Advisory Board
5/12/2020 12:00:34 AM
Sutro Biopharma Announces Pricing Of 11 Mln Shares At $7.75/Shr
5/11/2020 4:04:15 PM
Sutro Biopharma Announces Proposed Public Offering
4/27/2020 12:03:43 AM
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data For Dose Escalation Study Of STRO-002